Orca-T Expanded Access Program Study for Patients With Advanced Hematologic Malignancies
Public ClinicalTrials.gov record NCT07346105. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Expanded Access Program for Orca-T Products That Are Out of Specification for Commercial Release
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study is not designed to test a hypothesis; rather, this study will provide patients with access to Orca-T if the commercial Orca-T product produced for them is deemed out of specification (OOS). Serious adverse events (SAEs) occurring during the safety reporting period (defined as the day the recipient receives the Orca-T HSPC drug product through day +365 after transplantation or until initiation of new anticancer therapy, whichever occurs sooner) will be reported.
Study identification
- NCT ID
- NCT07346105
- Recruitment status
- Available
- Study type
- Expanded access
- Phase
- Not listed
- Enrollment
- Not listed
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- Not listed
- Sex
- All
- Healthy volunteers
- Not listed
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Not listed
- Primary completion
- Not listed
- Completion
- Not listed
- Last update posted
- Sep 20, 2026
United States locations
- U.S. sites
- 8
- U.S. states
- 7
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UCLA Department of Medicine - Hematology/Oncology | Los Angeles | California | 90095 | Available |
| Stanford Cancer Institute | Palo Alto | California | 94304 | Available |
| Moffitt Cancer Center | Tampa | Florida | 33612 | Available |
| The University of Kansas Hospital | Kansas City | Kansas | 66160 | Available |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | Available |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | Available |
| The Ohio State University Wexner Medical Center - James Cancer Hospital | Columbus | Ohio | 43210 | Available |
| Baylor University Medical Center | Dallas | Texas | 75246 | Available |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07346105, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 20, 2026 · Synced Sep 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07346105 live on ClinicalTrials.gov.